• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
IBRX

IBRX

ImmunityBio, Inc.

NASDAQHealthcareBiotechnologyUS

USD7.18

-0.05 (-0.69%)

Rating:C

Company Profile

CEO

Richard Gerald Adcock

IPO Date

2015-07-28

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$7.23

Prev. Close

$7.23

Day Low

$7.03

Day High

$7.30

52W Low

$1.95

52W High

$12.43

Market Cap

$7.52B

Volume

8.87M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

7

Avg Positive

71.9%

Avg Negative

15.6%

Avg Neutral

12.6%

News Feed

ImmunityBio: Market Has Lost Contact Following Merger

Seeking Alpha·7/19/2021·↓ negative

ImmunityBio Shares Jump As It Plans To Start Testing Memory Cytokine-Enriched NK Cell Platform In Solid Tumors Patients

Benzinga·5/17/2021·↑ positive

ImmunityBio (IBRX) Stock: Over 10% Increase Explanation

Pulse2·5/17/2021·↑ positive

ImmunityBio: Remaining Bullish As Global Vaccine Apparatus Continues To Misfire

Seeking Alpha·4/16/2021·↑ positive

ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data

Zacks Investment Research·4/9/2021·↑ positive

Single Dose Of ImmunityBio's Dual Antigen COVID-19 Vaccine Induces Ten-Fold Increase In T-Cell Responses

Benzinga·4/8/2021·↑ positive

ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2

Business Wire·4/8/2021·↑ positive